search
Back to results

A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants

Primary Purpose

Poliomyelitis

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
sIPV vaccine /DTaP vaccine
sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine
Sponsored by
Sinovac Biotech Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Poliomyelitis

Eligibility Criteria

2 Months - 18 Months (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Infants aged 2-3 months should be involved in primary immunization and they have not received Sabin strain inactivated polio vaccine (Vero Cell) in the past;
  • Children aged 18 months should be immunized with the first three doses of Sabin strain inactivated polio vaccine (Vero Cell) and they have not received any inactivated or attenuated live vaccines in the past 14 days;
  • The guardian agrees to sign the informed consent and voluntarily use the mobile APP to participate in the follow-up visits.

Exclusion Criteria:

  • Allergic to the active ingredient in the vaccine, any inactive ingredient, or substance used in the manufacturing process;
  • Allergic to this product or similar vaccines in the past;
  • Patients with severe chronic diseases or allergies;
  • Patients with fever or acute illness.

The Exclusion Criteria for the Second and Third Doses:

  • Any serious adverse events that are causally related to vaccination;
  • Severe anaphylaxis or hypersensitivity after vaccination (including hives and rashes within 30 minutes of vaccination);
  • Any confirmed or suspected autoimmune or immunodeficiency disease, including human immunodeficiency virus (HIV) infection;
  • Acute or newly emerging chronic diseases occur at the time of vaccination;
  • Other reactions (including severe pain, severe swelling, severe limitation of movement, persistent high fever, severe headache, or other systemic or local reactions), as determined by the investigator;
  • Having an acute illness at the time of vaccination (acute illness is defined as moderate or severe illness with or without fever);
  • Axillary temperature >37℃ during vaccination.

Sites / Locations

  • Gaoan Center for Disease Control and Prevention
  • Shangli County Center for Disease Control and Prevention

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Primary immunization group

Booster immunization group of sIPV vaccine

Arm Description

A total of 2000 infants aged 2-3 months will randomly assigned to two groups according to 1:1 using scratch cards: 1000 infants in the sIPV vaccine group and 1000 infants in the sIPV vaccine group plus DTaP vaccine group

A total of 1200 children aged 18 months will randomly assigned to four groups according to 2:2:1:1 using scratch cards: 400 in the sIPV booster group, 400 in the sIPV booster group plus inactivated hepatitis A vaccine simultaneously, 200 in the sIPV booster group plus MMR simultaneously, and 200 in the sIPV booster group plus attenuated hepatitis A vaccine.

Outcomes

Primary Outcome Measures

Incidence of adverse reactions within 0~7 days after primary immunization of sIPV vaccine
Incidence of adverse reactions within 0~7 days after primary immunization of sIPV vaccine

Secondary Outcome Measures

Incidence of adverse reactions within 0~30 days after primary immunization of sIPV vaccine
Incidence of adverse reactions within 0~30 days after primary immunization of sIPV vaccine.
Incidence of adverse reactions within 0~7 days after booster immunization of sIPV vaccine
Incidence of adverse reactions within 0~7 days after booster immunization of sIPV vaccine .
Incidence of adverse reactions within 0~30 days after booster immunization of sIPV vaccine
Incidence of adverse reactions within 0~30 days after booster immunization of sIPV vaccine.
Incidence of adverse reactions within 0-7 days after primary immunization of sIPV vaccine combined with DTaP vaccine
Incidence of adverse reactions within 0-7 days after primary immunization of sIPV vaccine combined with DTaP vaccine.
Incidence of adverse reactions within 0-30 days after primary immunization of sIPV vaccine
Incidence of adverse reactions within 0-30 days after primary immunization of sIPV vaccine combined with DTaP vaccine.
Incidence of adverse reactions after booster immunization of sIPV vaccine combined with inactivated hepatitis A vaccine
Incidence of adverse reactions within 0~7 days after booster immunization of sIPV vaccine combined with inactivated hepatitis A vaccine.
Incidence of adverse reactions within 0 ~14 days after booster immunization of sIPV vaccine
Incidence of adverse reactions within 0 ~14 days after booster immunization of sIPV vaccine combined with MMR vaccine or attenuated hepatitis A vaccine.
Incidence of adverse events within 0 ~ 30 days after booster immunization of sIPV vaccine
Incidence of adverse events within 0 ~ 30 days after booster immunization of sIPV vaccine combined with MMR vaccine ,inactivated hepatitis A vaccine or attenuated hepatitis A vaccine.

Full Information

First Posted
June 20, 2022
Last Updated
January 11, 2023
Sponsor
Sinovac Biotech Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT05432141
Brief Title
A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants
Official Title
Safety Observation of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in Primary Immunization, Booster Immunization and Simultaneous Vaccination With Other Vaccines in Infants
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
June 13, 2022 (Actual)
Primary Completion Date
September 13, 2022 (Actual)
Study Completion Date
December 13, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sinovac Biotech Co., Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety of Sabin Inactivated Poliovirus Vaccine (Vero cell)(sIPV)in the primary immunization of infants at the age of 2 months and booster immunization of children at the age of 18 months, and the simultaneous immunization with other vaccines of children at the age of 2 months and older, so as to provide reference for the improvement of immunization strategy.
Detailed Description
This study is an open and observational phase Ⅳ clinical trial of Sabin Inactivated Poliovirus Vaccine.The purpose of this study is to evaluate the safety of Sabin Inactivated Poliovirus Vaccine (Vero cell)(sIPV)in the primary immunization of infants at the age of 2 months and booster immunization of children at the age of 18 months, and the simultaneous immunization with other vaccines of children at the age of 2 months and older, so as to provide reference for the improvement of immunization strategy.A total of 3200 subjects including 2000 subjects aged 2~3 months in primary immunization group,1200 subjects aged 18 months in primary immunization group will be enrolled and will receive sIPV vaccine or sIPV vaccine and other vaccines simultaneously.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Poliomyelitis

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
3200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Primary immunization group
Arm Type
Experimental
Arm Description
A total of 2000 infants aged 2-3 months will randomly assigned to two groups according to 1:1 using scratch cards: 1000 infants in the sIPV vaccine group and 1000 infants in the sIPV vaccine group plus DTaP vaccine group
Arm Title
Booster immunization group of sIPV vaccine
Arm Type
Experimental
Arm Description
A total of 1200 children aged 18 months will randomly assigned to four groups according to 2:2:1:1 using scratch cards: 400 in the sIPV booster group, 400 in the sIPV booster group plus inactivated hepatitis A vaccine simultaneously, 200 in the sIPV booster group plus MMR simultaneously, and 200 in the sIPV booster group plus attenuated hepatitis A vaccine.
Intervention Type
Biological
Intervention Name(s)
sIPV vaccine /DTaP vaccine
Intervention Description
All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines. Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
Intervention Type
Biological
Intervention Name(s)
sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine
Intervention Description
All subjects will receive 1 dose of sIPV and 2 doses of hepatitis A inactivated vaccine/or 1 dose of attenuated hepatitis A vaccine and 1 dose of MMR vaccine.Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
Primary Outcome Measure Information:
Title
Incidence of adverse reactions within 0~7 days after primary immunization of sIPV vaccine
Description
Incidence of adverse reactions within 0~7 days after primary immunization of sIPV vaccine
Time Frame
Within 0~7 days after primary immunization
Secondary Outcome Measure Information:
Title
Incidence of adverse reactions within 0~30 days after primary immunization of sIPV vaccine
Description
Incidence of adverse reactions within 0~30 days after primary immunization of sIPV vaccine.
Time Frame
Within 0~30 days after primary immunization
Title
Incidence of adverse reactions within 0~7 days after booster immunization of sIPV vaccine
Description
Incidence of adverse reactions within 0~7 days after booster immunization of sIPV vaccine .
Time Frame
Within 0~7 days after booster immunization
Title
Incidence of adverse reactions within 0~30 days after booster immunization of sIPV vaccine
Description
Incidence of adverse reactions within 0~30 days after booster immunization of sIPV vaccine.
Time Frame
Within 0~30 days after booster immunization
Title
Incidence of adverse reactions within 0-7 days after primary immunization of sIPV vaccine combined with DTaP vaccine
Description
Incidence of adverse reactions within 0-7 days after primary immunization of sIPV vaccine combined with DTaP vaccine.
Time Frame
Within 0-7 days after primary immunization combined with DTaP vaccine
Title
Incidence of adverse reactions within 0-30 days after primary immunization of sIPV vaccine
Description
Incidence of adverse reactions within 0-30 days after primary immunization of sIPV vaccine combined with DTaP vaccine.
Time Frame
Within 0-30 days after primary immunization combined with DTaP vaccine
Title
Incidence of adverse reactions after booster immunization of sIPV vaccine combined with inactivated hepatitis A vaccine
Description
Incidence of adverse reactions within 0~7 days after booster immunization of sIPV vaccine combined with inactivated hepatitis A vaccine.
Time Frame
Within 0~7 days after booster immunization combined with inactivated hepatitis A vaccine
Title
Incidence of adverse reactions within 0 ~14 days after booster immunization of sIPV vaccine
Description
Incidence of adverse reactions within 0 ~14 days after booster immunization of sIPV vaccine combined with MMR vaccine or attenuated hepatitis A vaccine.
Time Frame
Within 0 ~14 days after booster immunization
Title
Incidence of adverse events within 0 ~ 30 days after booster immunization of sIPV vaccine
Description
Incidence of adverse events within 0 ~ 30 days after booster immunization of sIPV vaccine combined with MMR vaccine ,inactivated hepatitis A vaccine or attenuated hepatitis A vaccine.
Time Frame
Within 0 ~ 30 days after booster immunization of sIPV vaccine combined with MMR vaccine ,inactivated hepatitis A vaccine or attenuated hepatitis A vaccine.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Months
Maximum Age & Unit of Time
18 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Infants aged 2-3 months should be involved in primary immunization and they have not received Sabin strain inactivated polio vaccine (Vero Cell) in the past; Children aged 18 months should be immunized with the first three doses of Sabin strain inactivated polio vaccine (Vero Cell) and they have not received any inactivated or attenuated live vaccines in the past 14 days; The guardian agrees to sign the informed consent and voluntarily use the mobile APP to participate in the follow-up visits. Exclusion Criteria: Allergic to the active ingredient in the vaccine, any inactive ingredient, or substance used in the manufacturing process; Allergic to this product or similar vaccines in the past; Patients with severe chronic diseases or allergies; Patients with fever or acute illness. The Exclusion Criteria for the Second and Third Doses: Any serious adverse events that are causally related to vaccination; Severe anaphylaxis or hypersensitivity after vaccination (including hives and rashes within 30 minutes of vaccination); Any confirmed or suspected autoimmune or immunodeficiency disease, including human immunodeficiency virus (HIV) infection; Acute or newly emerging chronic diseases occur at the time of vaccination; Other reactions (including severe pain, severe swelling, severe limitation of movement, persistent high fever, severe headache, or other systemic or local reactions), as determined by the investigator; Having an acute illness at the time of vaccination (acute illness is defined as moderate or severe illness with or without fever); Axillary temperature >37℃ during vaccination.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shicheng Guo, Master
Organizational Affiliation
Jiangxi Provincial Center for Disease Prevention and Control
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gaoan Center for Disease Control and Prevention
City
Gao'an
State/Province
Jiangxi
ZIP/Postal Code
330899
Country
China
Facility Name
Shangli County Center for Disease Control and Prevention
City
Pingxiang
State/Province
Jiangxi
Country
China

12. IPD Sharing Statement

Learn more about this trial

A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants

We'll reach out to this number within 24 hrs